Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 24, Issue 4, Pages 417-442
Publisher
Informa Healthcare
Online
2014-01-30
DOI
10.1517/13543776.2014.877890
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588
- (2013) Paul W. Manley et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012
- (2013) Brian W Dymock et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish
- (2013) Sheng Yao et al. PLoS One
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Treatment ofALK-Positive Non–Small Cell Lung Cancer
- (2012) Yung-Jue Bang ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit
- (2012) Xianming Deng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
- (2012) Simon Giroux BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The battle against ALK resistance: successes and setbacks
- (2012) Claudia Voena et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibitors of the anaplastic lymphoma kinase
- (2012) Luca Mologni EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors
- (2012) Marian C. Bryan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase
- (2012) Diane E. Gingrich et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
- (2012) Richard T. Lewis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treating ALK-positive lung cancer—early successes and future challenges
- (2012) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase
- (2012) Keith S. Learn et al. MedChemComm
- Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
- (2011) Kazutomo Kinoshita et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
- (2011) Kazutomo Kinoshita et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors
- (2011) Craig A. Zificsak et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
- (2011) Linda R. Weinberg et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
- (2011) Craig A. Zificsak et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- 2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation
- (2011) Kevin J. Wells-Knecht et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors
- (2011) Gustav Boije af Gennäs et al. ChemMedChem
- Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-f][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors
- (2011) Eugen F. Mesaros et al. JOURNAL OF MEDICINAL CHEMISTRY
- 2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity
- (2011) Gregory R. Ott et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
- (2011) Kazutomo Kinoshita et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles
- (2011) Henry J. Breslin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
- (2011) M. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
- (2011) O. Merkel et al. MOLECULAR CANCER THERAPEUTICS
- Managing the challenge of chemically reactive metabolites in drug development
- (2011) B. Kevin Park et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery and Process Synthesis of Novel 2,7-Pyrrolo[2,1-f][1,2,4]triazines
- (2011) Tho Thieu et al. ORGANIC LETTERS
- Development and Scale-Up of an Optimized Route to the ALK Inhibitor CEP-28122
- (2011) Shawn P. Allwein et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models
- (2010) Eugen F. Mesaros et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibitors of anaplastic lymphoma kinase: a patent review
- (2010) Karen L Milkiewicz et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
- (2010) Gregory R. Ott et al. ACS Medicinal Chemistry Letters
- Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)
- (2009) Christopher J. Burns et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
- (2009) Thomas R Webb et al. Expert Review of Anticancer Therapy
- Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery
- (2008) Arup K. Ghose et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started